T. Rowe Price Associates’s Monte Rosa Therapeutics GLUE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $28.5M | Sell |
6,325,658
-318,478
| -5% | -$1.44M | ﹤0.01% | 880 |
|
|
2025
Q1 | $30.8M | Sell |
6,644,136
-472,501
| -7% | -$2.19M | ﹤0.01% | 852 |
|
|
2024
Q4 | $49.4M | Buy |
7,116,637
+515,496
| +8% | +$3.58M | 0.01% | 758 |
|
|
2024
Q3 | $35M | Buy |
6,601,141
+623,554
| +10% | +$3.3M | ﹤0.01% | 852 |
|
|
2024
Q2 | $22.4M | Buy |
5,977,587
+880,800
| +17% | +$3.29M | ﹤0.01% | 934 |
|
|
2024
Q1 | $35.9M | Buy |
5,096,787
+155,880
| +3% | +$1.1M | ﹤0.01% | 815 |
|
|
2023
Q4 | $27.9M | Buy |
4,940,907
+1,070,360
| +28% | +$6.05M | ﹤0.01% | 863 |
|
|
2023
Q3 | $18.5M | Sell |
3,870,547
-25,951
| -0.7% | -$124K | ﹤0.01% | 932 |
|
|
2023
Q2 | $26.7M | Buy |
3,896,498
+203,004
| +5% | +$1.39M | ﹤0.01% | 855 |
|
|
2023
Q1 | $28.8M | Buy |
3,693,494
+10,064
| +0.3% | +$78.4K | ﹤0.01% | 827 |
|
|
2022
Q4 | $28M | Sell |
3,683,430
-79,956
| -2% | -$608K | ﹤0.01% | 826 |
|
|
2022
Q3 | $30.7M | Sell |
3,763,386
-1,485,749
| -28% | -$12.1M | 0.01% | 776 |
|
|
2022
Q2 | $50.8M | Sell |
5,249,135
-101,788
| -2% | -$984K | 0.01% | 867 |
|
|
2022
Q1 | $75M | Buy |
5,350,923
+1,204,004
| +29% | +$16.9M | 0.01% | 827 |
|
|
2021
Q4 | $84.7M | Buy |
4,146,919
+999,985
| +32% | +$20.4M | 0.01% | 817 |
|
|
2021
Q3 | $69.3M | Buy |
3,146,934
+409,280
| +15% | +$9.01M | 0.01% | 900 |
|
|
2021
Q2 | $61.3M | Buy |
+2,737,654
| New | +$61.3M | 0.01% | 963 |
|